Miren Ettcheto

List of Publications by Year
in descending order

71	3,413	186265 28	144013 57
papers	citations	h-index	g-index

74	74	74	4896
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Metal-Based Nanoparticles as Antimicrobial Agents: An Overview. Nanomaterials, 2020, 10, 292.	4.1	769
2	Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model. Journal of Controlled Release, 2019, 301, 62-75.	9.9	207
3	Current Research Therapeutic Strategies for Alzheimerâ€™s Disease Treatment. Neural Plasticity, 2016, 2016, 1-15.	2.2	200
4	Memantine loaded PLGA PEGylated nanoparticles for Alzheimerâ€™s disease: in vitro and in vivo characterization. Journal of Nanobiotechnology, 2018, 16, 32.	9.1	163
5	Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. Journal of Alzheimer's Disease, 2018, 62, 1223-1240.	2.6	150
6	Current Applications of Nanoemulsions in Cancer Therapeutics. Nanomaterials, 2019, 9, 821.	4.1	147
7	Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents. Pharmaceutics, 2019, 11, 460.	4.5	115
8	PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofenâ€”in vitro, ex vivo and in vivo characterization. Colloids and Surfaces B: Biointerfaces, 2016, 145, 241-250.	5.0	108
9	Long-term exposition to a high fat diet favors the appearance of Î²-amyloid depositions in the brain of C57BL/6J mice. A potential model of sporadic Alzheimerâ€™s disease. Mechanisms of Ageing and Development, 2017, 162, 38-45.	4.6	79
10	Memantineâ€Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma. Small, 2018, 14, 1701808.	10.0	77
11	Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases. Nanomedicine, 2020, 15, 1239-1261.	3.3	68
12	New potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1171-1182.	3.3	64
13	Masitinib for the treatment of mild to moderate Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2015, 15, 587-596.	2.8	63
14	Epigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1073-1085.	3.3	60
15	Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimerâ€™s disease: from current to future challenges. Journal of Nanobiotechnology, 2021, 19, 122.	9.1	60
16	ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker. Biomedicine and Pharmacotherapy, 2019, 113, 108661.	5.6	52
17	Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice. Molecular Neurobiology, 2020, 57, 1814-1827.	4.0	51
18	Evaluation of Neuropathological Effects of a High-Fat Diet in a Presymptomatic Alzheimerâ€™s Disease Stage in APP/PS1 Mice. Journal of Alzheimer's Disease, 2016, 54, 233-251.	2.6	46

#	Article	IF	Citations
19	Review of the advances in treatment for Alzheimer disease: strategies for combating Î²-amyloid protein. NeurologÃa (English Edition), 2018, 33, 47-58.	0.4	46
20	The Implication of the Brain Insulin Receptor in Late Onset Alzheimerâ€™s Disease Dementia. Pharmaceuticals, 2018, 11, 11.	3.8	45
21	Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice. Journal of Medicinal Chemistry, 2021, 64, 812-839.	6.4	45
22	Dexibuprofen Biodegradable Nanoparticles: One Step Closer towards a Better Ocular Interaction Study. Nanomaterials, 2020, 10, 720.	4.1	44
23	The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimerâ€™s Dementia. Frontiers in Aging Neuroscience, 2019, 11, 236.	3.4	40
24	State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections. Journal of Nanobiotechnology, 2020, 18, 156.	9.1	38
25	Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways. Redox Biology, 2017, 13, 345-352.	9.0	36
26	Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia. Frontiers in Aging Neuroscience, 2019, 11, 344.	3.4	35
27	Experimental Models for Aging and their Potential for Novel Drug Discovery. Current Neuropharmacology, 2018, 16, 1466-1483.	2.9	35
28	The role of leptin in the sporadic form of Alzheimer's disease. Interactions with the adipokines amylin, ghrelin and the pituitary hormone prolactin. Life Sciences, 2015, 140, 19-28.	4.3	34
29	JNK1 inhibition by Licochalcone A leads to neuronal protection against excitotoxic insults derived of kainic acid. Neuropharmacology, 2018, 131, 440-452.	4.1	28
30	Lipid Nanoparticles for the Posterior Eye Segment. Pharmaceutics, 2022, 14, 90.	4.5	28
31	Epilepsy in Neurodegenerative Diseases: Related Drugs and Molecular Pathways. Pharmaceuticals, 2021, 14, 1057.	3.8	27
32	Surface Functionalization of PLGA Nanoparticles to Increase Transport across the BBB for Alzheimerâ€™s Disease. Applied Sciences (Switzerland), 2021, 11, 4305.	2.5	26
33	Targeting brain Renin-Angiotensin System for the prevention and treatment of Alzheimerâ€™s disease: Past, present and future. Ageing Research Reviews, 2022, 77, 101612.	10.9	26
34	Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 7327-7339.	4.0	24
35	Early Preclinical Changes in Hippocampal CREB-Binding Protein Expression in a Mouse Model of Familial Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 4885-4895.	4.0	21
36	JNK Isoforms Are Involved in the Control of Adult Hippocampal Neurogenesis in Mice, Both in Physiological Conditions and in an Experimental Model of Temporal Lobe Epilepsy. Molecular Neurobiology, 2019, 56, 5856-5865.	4.0	20

#	Article	IF	Citations
37	Hypercholesterolemia and neurodegeneration. Comparison of hippocampal phenotypes in LDLr knockout and APPswe/PS1dE9 mice. Experimental Gerontology, 2015, 65, 69-78.	2.8	19
38	Evaluation of the Role of JNK1 in the Hippocampus in an Experimental Model of Familial Alzheimerâ€™s Disease. Molecular Neurobiology, 2016, 53, 6183-6193.	4.0	19
39	Role of JNK isoforms in the kainic acid experimental model of epilepsy and neurodegeneration. Frontiers in Bioscience - Landmark, 2017, 22, 795-814.	3.0	19
40	A metabolic perspective of late onset Alzheimerâ€™s disease. Pharmacological Research, 2019, 145, 104255.	7.1	19
41	Metformin a Potential Pharmacological Strategy in Late Onset Alzheimerâ€™s Disease Treatment. Pharmaceuticals, 2021, 14, 890.	3.8	19
42	Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment. International Journal of Molecular Sciences, 2020, 21, 255.	4.1	18
43	Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acidÂnanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice. Nanomedicine, 2021, 16, 19-35.	3.3	18
44	Anti-inflammatory role of Leptin in glial cells through p38 MAPK pathway inhibition. Pharmacological Reports, 2017, 69, 409-418.	3.3	15
45	Development and optimization of Riluzole-loaded biodegradable nanoparticles incorporated in a mucoadhesive in situ gel for the posterior eye segment. International Journal of Pharmaceutics, 2022, 612, 121379.	5.2	15
46	Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation. Pharmaceutics, 2022, 14, 285.	4.5	15
47	Masitinib for the treatment of Alzheimer's disease. Neurodegenerative Disease Management, 2021, 11, 263-276.	2.2	14
48	Biodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges. Epilepsia Open, 2022, 7, .	2.4	14
49	Pharmacological Strategies to Improve Dendritic Spines in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 82, S91-S107.	2.6	13
50	A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease. Current Pharmaceutical Design, 2020, 26, 1286-1299.	1.9	12
51	State of the Art on Toxicological Mechanisms of Metal and Metal Oxide Nanoparticles and Strategies to Reduce Toxicological Risks. Toxics, 2021, 9, 195.	3.7	11
52	The Ethyl Acetate Extract of Leaves of Ugni molinae Turcz. Improves Neuropathological Hallmarks of Alzheimerâ€™s Disease in Female APPswe/PS1dE9 Mice Fed with a High Fat Diet. Journal of Alzheimer's Disease, 2018, 66, 1175-1191.	2.6	10
53	c-Jun N-terminal Kinase 1 ablation protects against metabolic-induced hippocampal cognitive impairments. Journal of Molecular Medicine, 2019, 97, 1723-1733.	3.9	10
54	Mice Lacking Functional Fas Death Receptors Are Protected from Kainic Acid-Induced Apoptosis in the Hippocampus. Molecular Neurobiology, 2015, 52, 120-129.	4.0	9

#	Article	IF	Citations
55	Characterizing the multiple roles of FGFâ€2 in SOD1^{G93A} ALS mice in vivo and in vitro. Journal of Cellular Physiology, 2019, 234, 7395-7410.	4.1	9
56	Involvement of JNK1 in Neuronal Polarization During Brain Development. Cells, 2020, 9, 1897.	4.1	8
57	Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment. Pharmaceuticals, 2021, 14, 220.	3.8	8
58	c-Jun N-Terminal Kinases in Alzheimerâ€™s Disease: A Possible Target for the Modulation of the Earliest Alterations. Journal of Alzheimer's Disease, 2021, 82, S127-S139.	2.6	7
59	Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimerâ€™s disease in metabolically stressed APPswe/PS1dE9 mice. Cell and Bioscience, 2021, 11, 141.	4.8	7
60	Role of brain câ€Jun Nâ€terminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a highâ€fat diet preâ€clinical model. Journal of Neurochemistry, 2019, 149, 255-268.	3.9	6
61	Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimerâ€™s disease. Expert Opinion on Investigational Drugs, 2019, 28, 93-97.	4.1	5
62	The preclinical discovery and development of opicapone for the treatment of Parkinsonâ€™s disease. Expert Opinion on Drug Discovery, 2020, 15, 993-1003.	5.0	5
63	Dual Mkk4 and Mkk7 Gene Deletion in Adult Mouse Causes an Impairment of Hippocampal Immature Granule Cells. International Journal of Molecular Sciences, 2021, 22, 9545.	4.1	2
64	Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease. Neural Regeneration Research, 2019, 14, 1721.	3.0	2
65	JNK1 and JNK3: divergent functions in hippocampal metabolic-cognitive function. Molecular Medicine, 2022, 28, 48.	4.4	2
66	Peroxisomal Proliferator-Activated Receptor Î²/Î´ Deficiency Induces Cognitive Alterations. Frontiers in Pharmacology, 0, 13, .	3.5	2
67	Isoformâ€selective as opposed to complete depletion of fibroblast growth factor 2 (FGFâ€2) has no major impact on survival and gene expression in SOD1 G93A amyotrophic lateral sclerosis mice. European Journal of Neuroscience, 2019, 50, 3028-3045.	2.6	1
68	JNK isoforms control mammal adult hippocampal neurogenesis. Mexican Journal of Medical Research ICSA, 2020, 8, 5-12.	0.2	1
69	GSPE pre-treatment protects against long-term cafeteria diet-induced mitochondrial and inflammatory affectations in the hippocampus of rats. Nutritional Neuroscience, 2022, 25, 2627-2637.	3.1	1
70	EPIGALLOGATECHIN-3-GALLATE IMPROVES COGNITIVE DECLINE AND METABOLIC ALTERATIONS IN APP/PS1 FAMILIAL MODEL OF ALZHEIMER'S DISEASE FED WITH HIGH FAT DIET. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-32.	0.0	0
71	Therapeutic Strategies for Neurological Disorders: From Natural Compounds to Innovative Molecular Designs. Current Pharmaceutical Design, 2022, 28, i-ii.	1.9	0